INFORMATION FOR
News
Using bioadhesive nanoparticles from the laboratory of Dr. W. Mark Saltzman, Dr. Michael Girardi and his team collaborated with Dr. Saltzman and loaded them with a one-two punch of chemotherapy plus immunotherapy to study its impact in skin cancer. The results may have significant impact for how skin cancer tumors are treated.
Vida Chernoff lives life to the fullest after immunotherapy at Smilow Cancer Hospital
Colon cancer has been undergoing a similar subdivision. Researchers have known for years that colorectal cancer is the third most common cancer diagnosis in the United States and the second leading cause of cancer-related deaths. The National Cancer Institute estimates 149,500 new cases in 2021 and 53,000 deaths.
"Age and sex are where immunological changes intersect,” says Akiko Iwasaki, PhD. Over the past year, Iwasaki and her colleagues from around the globe have compiled a rich literature of research that reveals in detail these and other factors that make the virus more lethal for men.
Genetics, gender, and even botched timing on the part of the immune response all appear important in the development of COVID-19. Akiko Iwasaki, PhD, is leading research to help us better predict who is likely to sail through a bout with COVID-19 and who may need targeted lifesaving care.
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
“Having to adapt to different situations throughout my life prepared me [for] a different virus,” says Akiko Iwasaki of Yale University.
Women’s Health Research at Yale announced funding for a unique study focusing on sex differences in immune responses to SARS-CoV-2, the virus which causes COVID-19.
Yale Cancer Center (YCC) scientists presented research at the 61st annual American Society for Radiation Oncology (ASTRO) annual meeting in Chicago.
The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).
Yale Cancer Center (YCC) scientists have uncovered the workings of a metabolic pathway or “gauge” that lets cancer cells detect when they have enough nutrients around them to grow.
A new immunotherapy cancer drug boosts survival rate five-fold, scientists from Yale have found.
Bristol-Myers Squibb released the pooled efficacy and safety results from its Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced non-small cell lung cancer (NSCLC).
Yale Cancer Center (YCC) is proud to announce several leadership appointments, including two new senior positions to help bolster YCC’s research mission in the coming years.
A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system’s ability to attack a variety of tumor types, Yale Cancer Center researchers report Aug. 22 in the journal Cell.
A team of investigators at Yale Cancer Center (YCC) have found a major chink in the armor of an incurable childhood brain cancer called Diffuse Intrinsic Pontine Gliomas (DIPG).
Yale's review of the ASCO 2019 Annual Meeting was held in Westbrook, CT on June 14.
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.
Yale Cancer Center researchers have discovered how metastasis, the spread of cancer cells throughout the body, is triggered on the molecular level, and have developed a tool with the potential to detect those triggers in patients with certain cancers. The discovery could lead to new ways for treating cancer.
Vitamin D, the “sunshine vitamin,” may be helpful for people diagnosed with colon cancer, says Charles Fuchs, MD, MPH, director of Yale Cancer Center.